Filing Flows › Korro Bio (KRRO) › Q3 2025
Korro Bio (KRRO) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 12, 2025
Korro Bio (KRRO) reported revenue of $1.1M for the third quarter 2025 (Q3 2025) and -25% from the quarter before.
Korro Bio, Q3 2025: revenue $1.1M, net loss $18.1M, operating cash flow −$17.2M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.1M | -25% | — |
| Operating profit | −$19.2M | — | — |
| Net earnings | −$18.1M | — | — |
| Operating cash flow | −$17.2M | — | — |
What changed
Revenue was $1.1M in Q3 2025, down 25% from the previous quarter.
Operating costs exceeded revenue by $19.2M, an operating margin of -1764.9%. The quarter ended with a net loss of $18.1M, narrower than the previous quarter's $25.8M loss.
Operating cash flow was −$17.2M. Non-cash charges added back $1.2M of depreciation and $1.8M of share-based compensation. Working capital and other items used $2.1M. Capital expenditures of $175K exceeded it, leaving free cash flow of −$17.4M.
Questions
What was Korro Bio's revenue in the third quarter 2025?
Korro Bio (KRRO) reported revenue of $1.1M for the third quarter 2025 (Q3 2025) and -25% from the quarter before.
Source: Korro Bio 10-Q on SEC EDGAR.